Phase I/II study of Gemcitabine plus nab-paclitaxel and intraperitoneal paclitaxel for pancreas cancer with peritoneal metastasis
Not Applicable
- Conditions
- The patients with pancreatic cancer who have peritoneal metastasis diagnosed by staging laparoscopy or open laparotomy.
- Registration Number
- JPRN-UMIN000018878
- Lead Sponsor
- Study group of pancreatic cancer with peritoneal metastasis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Not provided
Exclusion Criteria
Metastasis to distant organ sites such as the liver, lungs or bone; other active concomitant malignancies; other severe medical conditions; contraindication of Gemcitabine, nab-paclitaxel or Paclitaxel, or Pregnant woman
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method One year survival rate
- Secondary Outcome Measures
Name Time Method